Navigation Links
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
Date:9/28/2007

CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R) and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K. The presentation, entitled "Biological Approaches to Radiosensitisation: Viruses, Gene Therapy and Novel Radiosensitisers" will be presented by Dr. Kevin Harrington of The Institute of Cancer Research, London and one of the principal investigators for the trial. The conference runs from September 30 through October 3, 2007 in Birmingham, U.K.

"We are very pleased with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to evaluate the data and look forward to announcing final results."

To date, 22 patients have been treated with 15 having completed the study. Five patients withdrew from the study, and two patients are still on study.

A total of 11 patients in the Ia portion of the trial received two intratumoural treatments of REOLYSIN(R) at dosages of 1x10(8), 1x10(9), or 1x10(10) TCID(50) with a constant localized radiation dose of 20 Gy given in five fractions. Of these 11 patients, three patients (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial responses.

One month following treatment, the oesophageal patient experienced a 28.5% reduction in the target tumour, with stable disease noted in four, non-treated tumours. At two and three months, the target tumour had shrunk 64%, with stable disease continuing in the four non-treated tumours, including a 15% volume reduction in non-treated mediastinal disease that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction in the t
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Guidance New Launches Should Contribute ... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced ... Quarter and Six Month Results, For the second quarter ... and a net loss of $20.1 million, or $0.60 per ...
... Aug. 7 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" ... into an arrangement agreement (the "Arrangement Agreement") dated,August ... ("Calyx"), a,wholly-owned subsidiary of Chromos, and Modatech Systems ... agreement have agreed to effect a plan,of arrangement ...
... CITY, Aug. 7 Thousands of AIDS activists,gathered today ... a key event of the XVII International AIDS Conference. ... protections,for people living with HIV and those most affected ... use drugs, and men who,have sex with men., ...
Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 2Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 3Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response 4
(Date:4/23/2014)... researcher has shed light on how an estimated one ... outback have become reviled as pests and culled on ... and Sustainability Institute at the University of Exeter,s Penryn ... from their historic role helping to create the country,s ... , The deserts of the Australian outback are a ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3
... State University researcher has demonstrated that a variety of environmental ... animal but the next three generations of its offspring. , ... the way genes turn on and offthe epigenetic effect studied ... on in the current issue of the online journal ...
... sizes. Scientists have discovered simple rules that control leaf shape during ... able to accurately emulate leaf growth from a bud. "A ... said lead author Samantha Fox from the John Innes Centre on ... bud, not flat with a pointed tip." By creating a ...
... On March 9, the New York Academy of Sciences ... of Established Regulatory Guidance." This full-day conference will explore ... challenges for follow-on versions of complex drugs. , On ... draft guidelines for implementing the Biologics Price Competition and ...
Cached Biology News:Effects of environmental toxicants reach down through generations 2First model of how buds grow into leaves 2Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference 2
Prepared from plasminogen by activation with immobilized human uPA...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human GFR alpha-4 Affinity Purified Polyclonal Ab...
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Biology Products: